Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies
These early-phase findings suggest that VG161 elicits meaningful immune activation in ICC and supports further investigation. By inducing both direct oncolysis and multilayered immune activation, VG161 shows clinical benefit in a heavily pretreated population and holds promise for integration with CPI-based regimens. Validation in larger trials is warranted.
Authors
- Zeda Zhao (ORCID: https://orcid.org/0000-0001-6104-702X)
- Hangyu Zhou (ORCID: https://orcid.org/0000-0002-3762-2319)
- Zhenglong Zhai
- Youlei Wang
- Xingmei Liang
- Guo‐Ming Shi (ORCID: https://orcid.org/0000-0003-3817-9117)
- Guyue Wei
- Peilin Lan
- Longshen Xie (ORCID: https://orcid.org/0000-0003-3256-0822)
- Chuntian Tu
- Zhuojun Zhou
- Sida Guo
- Xueyan Shi (ORCID: https://orcid.org/0000-0002-3181-9970)
- Xueli Bai (ORCID: https://orcid.org/0000-0002-2934-0880)
- Wendi Hu
- Tengjie Wu
- Danni Lin (ORCID: https://orcid.org/0009-0007-3923-2027)
- Jiejing Kai
- Tao Jiang (ORCID: https://orcid.org/0000-0003-0002-8890)
- Zifan Yang
- Xinyan Jin
- Yufu Ye (ORCID: https://orcid.org/0000-0002-4068-5273)
- Yuntao Zhang (ORCID: https://orcid.org/0000-0002-0557-5693)
- Enliang Li (ORCID: https://orcid.org/0000-0003-2988-0323)
- Zijun Wang (ORCID: https://orcid.org/0000-0002-2070-7025)
- William Jia (ORCID: https://orcid.org/0000-0002-2755-6821)
- Wei Song (ORCID: https://orcid.org/0000-0003-2679-1069)
- Xiaoyu Zhang
- Yuwei Li (ORCID: https://orcid.org/0000-0002-9290-6701)
- Jīng Li (ORCID: https://orcid.org/0000-0001-9714-5924)
- Wei Chen (ORCID: https://orcid.org/0000-0003-3611-2760)
- Xiang Li (ORCID: https://orcid.org/0000-0002-4675-5367)
- Siyuan Chen (ORCID: https://orcid.org/0000-0001-6146-5627)
- Lei Wang (ORCID: https://orcid.org/0000-0002-0336-7241)
- Fang Tian (ORCID: https://orcid.org/0000-0002-5631-7125)
- Yiwen Chen (ORCID: https://orcid.org/0000-0002-9008-8346)
- Qian Tan
- Ronghua Zhao (ORCID: https://orcid.org/0000-0001-8023-7128)
- Xingjiang Hu (ORCID: https://orcid.org/0000-0002-8579-625X)
- Zhe-Wei Zhang
- Xiaozhen Zhang (ORCID: https://orcid.org/0000-0003-3567-8789)
- Hongchao Zhang (ORCID: https://orcid.org/0000-0003-4998-6854)
- Hongwei Huang (ORCID: https://orcid.org/0009-0001-9741-5901)
- Xiaoli Sun
- Linghao Xia
- Yinan Shen
- Qingwei Zhao (ORCID: https://orcid.org/0000-0002-7201-0588)
- Jiaxin Li (ORCID: https://orcid.org/0009-0004-5511-9719)
- Tingbo Liang (ORCID: https://orcid.org/0000-0003-0143-3353)
- Jun Ding (ORCID: https://orcid.org/0000-0002-5923-3621)
- Z Shou
- Fang Wei
- Wei Dong Zhang (ORCID: https://orcid.org/0000-0002-8850-5235)
Institutions
- Nanchang University (CN)
- Sun Yat-sen University (CN)
- Fudan University (CN)
- China National Pharmaceutical Group Corporation (China) (CN)
- Zhejiang Cancer Hospital (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Viva Biotech (China) (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Gut
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1136/gutjnl-2025-335904
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00